Business Wire

AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

An OS hazard ratio assesses the relative risk of death for the entirety of the data set. TIVO-3 is the first and only positive Phase 3 study in 3 rd and 4 th line RCC, and the first Phase 3 study in ...
Nature

Survival Analysis and Treatment Effects in Clinical Trials

Survival analysis is an essential statistical framework employed to examine time-to-event data, frequently encountered in clinical trials. By properly accounting for censored observations—cases where ...
The New England Journal of Medicine

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year ...
Nasdaq

AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- AVEO Oncology (NASDAQ: AVEO) today announced results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial. TIVO-3 is the Company’s ...
Business Wire

AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma - 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on ...